REMAP-CAP
A global health challenge: Respiratory tract infections are the leading cause of deaths from infectious disease globally, and are the leading cause of deaths in developing nations.
An innovative approach to critical care research: REMAP-CAP uses a novel and innovative adaptive trial design to evaluate a number of treatment options simultaneously and efficiently. This design is able to adapt in the event of pandemics, and increases the likelihood that patients will receive the treatment that is most likely to be effective for them.
An international collaboration: REMAP-CAP is a global network of leading experts, institutions and research networks. With over 300 participating world-wide, REMAP-CAP is a truly global trial.
Pandemic preparedness: The REMAP-CAP trial provides a global research platform that is able to adapt to efficiently evaluate multiple treatment options for patients in a global respiratory pandemic.
For more information, please visit the REMAP-CAP website
Recent Publications
Effect of Hydrocortisone on Mortality and Organ Support in Patients with Severe COVID-19
Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19
Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients with COVID-19
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with COVID-19